glp-1 drug manufacturers The Technologies Propelling Analogues FDA's GLP-1 decision kicks off

Diabetes Care 48(1):S207-38 Marx N, Federici M, Schtt K, Mller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)

It means a 0.25mg weekly injection delivers more systemic semaglutide than a 1mg daily sublingual dose in many cases

WHAT EXACTLY ARE GLP-1 MEDICATIONS

Despite new insulin formulations and improvements in the technology of insulin pumps and continuous glucose monitoring, glycemic control continues to be suboptimal in T1D, with about 80% of patients not reaching the recommended goals

Zarghami also developed the kind of muscle weakness that would be expected only after running a marathon

Deo SV, Marsia S, McAllister DA, Elgudin Y, Sattar N, Pell JP